Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patient-reported outcome results from the US Life after Stopping TKIs (LAST) study in patients with chronic myeloid leukemia
    Meeting Abstract

    Flynn, K. E.; Weinfurt, K. P.; Lin, L.; Radich, J. P.; Schiffer, C. A.; Mauro, M. J.; Ibarz, J. P.; Moore, J. O.; Larson, R. A.; Oehler, V. G.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Maintenance decitabine (DAC) improves disease-free (DFS) and overall survival (OS) after intensive therapy for acute myeloid leukemia (AML) in older adults, particularly in FLT3-ITD-negative patients: ECOG-ACRIN (E-A) E2906 randomized study
    Meeting Abstract

    Foran, J. M.; Sun, Z.; Claxton, D. F.; Lazarus, H. M.; Arber, D. A.; Rowe, J. M.; Paietta, E.; Racevskis, J.; Altman, J. K.; Luger, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Enasidenib plus azacitidine significantly improves complete remission and overall response compared with azacitidine alone in patients with newly diagnosed acute myeloid leukemia (AML) with isocitrate dehydrogenase 2 (IDH2) mutations: Interim phase II results from an ongoing, randomized study
    Meeting Abstract

    DiNardo, C. D.; Schuh, A. C.; Stein, E. M.; Montesinos Fernandez, P.; Wei, A.; De Botton, S.; Zeidan, A. M.; Fathi, A. T.; Quek, L.; Kantarjian, H. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Molecular mechanisms mediating relapse following ivosidenib monotherapy in patients with IDH1-mutant relapsed or refractory acute myeloid leukemia
    Meeting Abstract

    Choe, S.; Wang, H.; DiNardo, C. D.; Stein, E. M.; De Botton, S.; Fathi, A. T.; Tallman, M. S.; Kantarjian, H. M.; Stone, R. M.; Quek, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Optimal dual-targeted CAR construct simultaneously targeting BCMA and GPRC5D prevents BCMA-escape driven relapse in multiple myeloma
    Meeting Abstract

    Fernandez de Larrea, C.; Staehr, M.; Lopez, A.; Chen, Y.; Purdon, T. J.; Ng, K. Y.; Wendel, H.; Brentjens, R. J.; Smith, E. L.
    Blood (2019)

    Fulltext@MSK | Save
  • Leukemia cell of origin influences p53 activity and therapeutic sensitivity via an Evi1-dependent mechanism
    Meeting Abstract

    Cai, S. F.; Chu, S.; Goldberg, A. D.; Parvin, S.; Koche, R.; Glass, J. L.; Stein, E. M.; Tallman, M. S.; Sen, F.; Famulare, C.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Precision medicine treatment in older AML: Results of beat AML master trial
    Meeting Abstract

    Burd, A.; Levine, R. L.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M. W.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Prevalence of inherited cancer predisposition mutations in a cohort of older AML patients enrolled on the beat AML master trial
    Meeting Abstract

    Borate, U.; Yang, F.; Press, R. D.; Pavlick, D.; Juckett, L.; Agarwal, A.; Burd, A.; Mims, A. S.; Stein, E. M.; Patel, P. A.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • TP53 state dictates genome stability, clinical presentation and outcomes in myelodysplastic syndromes
    Meeting Abstract

    Bernard, E.; Nannya, Y.; Yoshizato, T.; Hasserjian, R. P.; Saiki, R.; Shiozawa, Y.; Devlin, S. M.; Tuechler, H.; Sarian, A.; Malcovati, L.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • RAS mutations are independently associated with decreased overall survival and event-free survival in patients with AML receiving induction chemotherapy
    Meeting Abstract

    Ball, B. J.; Hsu, M.; Devlin, S. M.; Famulare, C.; Cai, S. F.; Dunbar, A.; Epstein-Peterson, Z. D.; Menghrajani, K.; Glass, J. L.; Taylor, J.; more...
    Blood (2019)

    Fulltext@MSK | Save